Abstract Library

#152 Validation of a new assay that uses 2 monoclonal antibodies to measure intact and fragmented plasma CgA levels

Introduction: Plasma chromogranin A (CgA) levels are elevated in a variety of neuroendocrine tumors (NETs) and are used to aid in diagnosis, prognosis, and monitoring of treatment effects in NETs patients. We evaluated a newer sandwich ELISA assay (Cisbio US, Bedford, MA, USA) that utilizes two monoclonal antibodies that bind to the mid-region of the CgA protein and allow measurement of intact and fragmented circulating CgA. The results from the assay validation indicative of its overall robustness in terms of sensitivity, specificity, reproducibility, and stability are presented here.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Motwani M, Nuti S, Tsuchihashi Z, Barrett J,

Keywords: chromogranin A, CgA, neuroendocrine tumor, pancreatic NETs, ELISA, biomarker,